Article

Bioptic telescope users rate high on driving safety test

Despite moderate central vision loss, 96% of drivers who used a bioptic telescope were rated safe to drive following an on-road driving performance test. These findings may guide the assessment and training of bioptic drivers and allow more of them to maintain independence, employment, and mobility within their communities, said Joanne M. Wood, PhD.

Fort Lauderdale, FL-Despite moderate central vision loss, 96% of drivers who used a bioptic telescope were rated safe to drive following an on-road driving performance test. These findings may guide the assessment and training of bioptic drivers and allow more of them to maintain independence, employment, and mobility within their communities, said Joanne M. Wood, PhD.

“This study shows that many drivers with moderate central vision loss have the ability and potential for safe driving using the bioptic telescope after appropriate training,” said Dr. Wood, School of Optometry, Queensland University of Technology, Brisbane, Australia.

Dr. Wood and colleagues designed a test of 23 bioptic drivers licensed to drive in Birmingham, AL, where the test took place, and 23 visually normal age-matched controls; the bioptic drivers had mean binocular visual acuity of 20/60 to 20/200, and their mean age was 32 years.

The 14.6-mile driving assessment included both suburban and city driving, starting in a church parking lot and progressing to intersections not controlled by traffic signals and controlled-access highways. The test participants drove a dual-brake vehicle with a certified driving rehabilitation specialist in the front seat and two raters in the back seat who evaluated 24 driving maneuvers associated with eight driving behaviors, such as scanning, lane position, steering steadiness, speed, and obeying signals.

Significant differences between the bioptic drivers and the controls were found for lane positioning, traffic light recognition, and steering steadiness. However, there were no significant differences between the groups for most of the driving performance measures, Dr. Wood said.

She also noted that the bioptic drivers made more right head movements and tended to drive over the right edge or lane marking more often.

In the overall safety ratings, only one bioptic driver was classified as unsafe; all drivers in the control group were rated safe.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.